A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.